SKYLA (levonorgestrel) by Bayer. Approved for progestin [epc]. First approved in 2013.
Drug data last refreshed 17h ago · AI intelligence enriched 20h ago
SKYLA is a levonorgestrel-releasing intrauterine system (IUS) approved by the FDA in January 2013 for contraception. It delivers a synthetic progestin directly to the reproductive tract to prevent pregnancy. The device is a small T-shaped system that provides long-acting reversible contraception for up to 3 years.
Product is in late-stage maturity with minimal Part D presence, indicating a small and shrinking commercial team focused on retention and line extension rather than growth.
Progestin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effects of Copper Versus Levonorgestrel Intrauterine Devices on Mucosal Microbiota and Barrier Function Among Young African Women
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Worked on SKYLA at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
SKYLA offers minimal career growth opportunity given its approaching loss of exclusivity and low Part D spending signal. Working on this product is primarily a maintenance role focused on defending market share against branded and future generic competitors within Bayer's contraceptive portfolio.